Molecular Endocrinology · 2007 · 34 citations · 36 references
MedicineMolecular BiologyOncologyGene ExpressionMolecular OncologyTranscriptional RegulationAndrogen Deprivation TherapyHormonal Cancer TherapyHormone ReceptorsNuclear ReceptorsProstate CancerSteroid Hormone SignalingAndrogen ReceptorsCorepressor RecruitmentHormone-receptor CorepressorsNuclear Hormone ReceptorsNuclear Receptor CorepressorsProstate Growth RegulationReceptor SumoylationSteroid Receptor Corepressors
Prostate cancer cell growth is initially androgen dependent. Androgen antagonists are used in prostate cancer therapy to inactivate the transcriptional activity of the human androgen receptor (hAR) and to inhibit the proliferation of prostate cancer. Here, we have characterized Alien with characteristics of a corepressor as a novel interacting factor for the antagonist bound hAR. Alien is recruited to hAR in the presence of the AR antagonist cyproterone acetate (CPA). The interaction of Alien with hAR is verified in vivo and in vitro by a modified mammalian two-hybrid system, coimmunoprecipitation, chromatin immunoprecipitation, and in vitro binding assays. In contrast to other nuclear receptors, Alien binds to the amino-terminus of hAR with the receptor SUMOylation (small ubiquitin modifier) sites being involved. Furthermore, cellular localization of Alien is changed towards a predominant nuclear localization upon treatment of prostate cancer cells with CPA. Notably, stable expression of Alien in LNCaP cells inhibits both endogenous prostate-specific antigen expression and proliferation of these cells in the presence of CPA but not in the presence of an AR agonist. These findings underline the importance of corepressors for inhibition of prostate cancer cell growth by androgen antagonists.
36
Estimates of the cancer incidence and mortality in Europe in 2006
Jacques Ferlay, Philippe Autier, Mathieu Boniol et al. · Annals of Oncology · 2007 · 4K citations · Full text
Estimates of cancer incidence and mortality in Europe in 1995
Freddie Bray, Risto Sankila, Jacques Ferlay et al. · European Journal of Cancer · 2002 · 688 citations
Formation of the Androgen Receptor Transcription Complex
Yongfeng Shang, Molly Myers, Myles Brown · Molecular Cell · 2002 · 666 citations · Full text
Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist.
Mary‐Ellen Taplin, Glenn J. Bubley, Yoo‐Joung Ko et al. · PubMed · 1999 · 599 citations · Full text
Medicine, Oncology, Pharmacology +17